Last reviewed · How we verify
T89 Low dose
T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease.
T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease. Used for Angina pectoris, Myocardial infarction, Heart failure.
At a glance
| Generic name | T89 Low dose |
|---|---|
| Also known as | Dantonic®, Salvtonic®, Compound Danshen Dripping Pill |
| Sponsor | Tasly Pharmaceuticals, Inc. |
| Drug class | Traditional Chinese medicine compound |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
T89 (Danshen dripping pill) contains multiple active components that enhance ATP production in cardiac mitochondria, improve coronary blood flow, and reduce oxidative stress and apoptosis in ischemic myocardium. The formulation works through multiple pathways including mitochondrial protection, anti-inflammatory effects, and improvement of cardiac contractility.
Approved indications
- Angina pectoris
- Myocardial infarction
- Heart failure
Common side effects
- Gastrointestinal upset
- Dizziness
- Headache
Key clinical trials
- Low-Thoracic Epidural Anesthesia For Laparoscopic Nephrectomy. (NA)
- Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina (PHASE3)
- Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (PHASE3)
- Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (PHASE2)
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (PHASE3)
- Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |